William Cronin to resign as CEO of Dignitana AB

Dignitana CEO William Cronin has notified the Board of Directors of his intention to resign as CEO. He will remain as CEO until the Dignitana AGM in May, after which time he will transition to serve as Deputy Chairman of the Board of Directors and will be a Senior Advisor to the company regarding US market and reimbursement strategies.

The process of recruiting a successor will begin immediately for a new CEO who will be based at the Company headquarters in Lund along with other key positions for the Company.

Klas Arildsson, Chairman of the Board, Dignitana AB:

"Dignitana’s clear strategy is to expand and further strengthen both the primary US market and our presence around the globe.  I want to thank William for his hard work, passion, and perseverance. We are now at an exciting stage with a solid foundation and great opportunities before us.  Under his leadership we have accessed significant US opportunities and regained the company’s position as a leader in innovation. William’s ongoing involvement with Dignitana will ensure not only a smooth transition to the new CEO, but also continued strategic expansion in the critical US market."

William Cronin, CEO, Dignitana AB:

"I am pleased with what we have accomplished over the past six years, especially the establishment of DigniCap in the US market, bringing this life changing therapy to thousands of people. One of our greatest assets is the passion and commitment of our team members, and I have been fortunate to see that impact every day. Dignitana has strong potential for growth in the near-term and I will remain actively involved in the company as a Senior Advisor focusing on the expansion of the US market access, as well as a member of the Board and as a significant shareholder."

William Cronin has been CEO of Dignitana AB since November 2017. He previously served as CEO of Dignitana, Inc. beginning in December 2015 when the company’s U.S. subsidiary was established. Under his leadership DigniCap became the first scalp cooling device to receive FDA clearance, with clinical indications then expanded in 2017. Cronin then led the development of the next generation DigniCap Delta device which received FDA clearance in 2019.